Clinical Pharmacology and Internal Diseases Exam Study Guide 2024-2025 Comprehensive Study Notes

Foundations of Clinical Pharmacology and Pharmacotherapy

• Clinical Pharmacology: Subject, Structure, Tasks, and Role in Medicine

  • Subject: The study of drug effects and their optimal use in humans.

  • Structure:

    • Pharmacokinetics: Study of drug movement through the body.

    • Pharmacodynamics: Study of drug effects on the body.

    • Clinical Trials: Research involving human subjects.

    • Therapeutic Monitoring: Measuring drug levels to optimize therapy.

  • Tasks:

    • Development of safe, effective, and evidence-based treatments.

    • Personalization of therapy for individual patients.

  • Role: Bridges the gap between basic pharmacology and clinical practice. It ensures rational prescribing and minimizes adverse effects, which is critical for patient safety in dentistry and medicine.

• Types of Pharmacotherapy and Principles of Rational Pharmacotherapy

  • Types:

    • Empirical: Based on clinical judgment; e.g., administering antibiotics before culture results are available.

    • Symptomatic: Focused on relieving symptoms; e.g., using ibuprofen for dental pain.

    • Causal: Targeting the direct cause of a disease; e.g., using penicillin for a streptococcal infection.

    • Replacement: Substituting deficient substances; e.g., levothyroxine for hypothyroidism.

  • Principles of Rational Pharmacotherapy:

    • Goal-oriented drug selection based on evidence.

    • Maximizing efficacy while minimizing adverse effects.

    • Consideration of patient-specific factors such as allergies and renal function.

  • Objectives: Effective treatment, safety, cost-effectiveness, and ensuring patient adherence.

• Terminology in Clinical Pharmacology and Pharmacotherapy

  • Biologically Active Substance: A chemical that alters physiological processes (e.g., caffeine).

  • Drug: A substance used for the diagnosis, treatment, or prevention of disease (e.g., amoxicillin).

  • Dosage Form: The method by which a drug is delivered (e.g., tablets, syrups, injectables).

  • International Nonproprietary Name (INN): The standardized generic name of a drug (e.g., ibuprofen).

  • Original Drug: A patented, brand-name drug (e.g., Advil).

  • Generic Drug: A bioequivalent version of the original drug, marketed after the patent has expired (e.g., generic ibuprofen).

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

• Pharmacokinetic Concepts and Parameters

  • Definition: The study of drug absorption, distribution, metabolism, and excretion ($\text{ADME}$).

  • Challenges: Interpatient variability caused by genetics, liver function, and other factors.

  • Opportunities: Personalized dosing through clinical monitoring.

  • Therapeutic Effect: The desired clinical outcome; e.g., pain relief provided by paracetamol.

  • Therapeutic Index ($TI$): The safety margin of a drug, calculated as $\frac{TD_{50}}{ED_{50}}$. A narrow index is seen in drugs like warfarin.

  • Therapeutic Drug Monitoring ($TDM$): Measuring plasma levels to optimize dosing; e.g., maintaining vancomycin levels between $10-20\,\mu g/mL$.

  • Maintenance Dose: The dose required to sustain a therapeutic effect; e.g., warfarin $2-5\,mg/day$ for anticoagulation.

  • Half-Life ($t_{1/2}$): The time required for the drug concentration to decrease by half; e.g., amoxicillin is approximately $1-2\,\text{hours}$. This determines dosing frequency.

  • Clearance ($Cl$): The rate of drug elimination via renal or hepatic pathways; e.g., gentamicin renal clearance. This affects steady-state drug levels.

• Absorption and Transport Mechanisms

  • Absorption: The entry of a drug into the bloodstream from the site of administration.

  • Transport through Biomembranes:

    • Passive Diffusion: Driven by the concentration gradient; typical for lipophilic drugs like diazepam.

    • Active Transport: Energy-dependent and works against a concentration gradient; e.g., levodopa.

    • Facilitated Diffusion: Carrier-mediated transport that does not require energy; e.g., glucose analogs.

  • Factors Affecting Absorption: pH levels, surface area, and blood flow. For instance, absorption is faster in the small intestine.

• Distribution and Protein Binding

  • Distribution: The spread of a drug to tissues after absorption, influenced by blood flow, tissue affinity, and protein binding.

  • Volume of Distribution ($V_d$): A hypothetical volume a drug occupies.

    • Warfarin $V_d \approx 8\,L$ (highly protein-bound).

    • Digoxin $V_d \approx 500\,L$ (highly tissue-bound).

  • Significance: A high $V_d$ indicates extensive tissue distribution, which affects dosing requirements.

  • Protein Binding: Drugs bind to plasma proteins such as albumin, reducing the free (active) fraction.

    • High binding (e.g., warfarin $99\%$ bound) prolongs action and delays clearance.

    • Displacement by other drugs (e.g., NSAIDs) increases free drug levels, risking toxicity such as warfarin-induced bleeding.

• Metabolism and Excretion

  • Biotransformation: Occurs primarily in the liver to convert drugs into active or inactive metabolites.

    • Phase I: Oxidation, reduction, and hydrolysis; e.g., cytochrome $P450$ converting codeine to morphine.

    • Phase II: Conjugation; e.g., glucuronidation of paracetamol.

  • Genetic Variability: Variations in enzymes like $CYP2C9$ affect the metabolism of drugs like warfarin.

  • Renal Excretion: The primary route of drug elimination via the kidneys.

    • Glomerular Filtration: For free drugs like gentamicin.

    • Tubular Secretion: Active transport mechanism; e.g., for penicillin.

    • Reabsorption: Lipophilic drugs are often reabsorbed into the system.

  • Clinical Note: Impaired renal function (e.g., Chronic Kidney Disease) requires dose adjustment, such as reducing the gentamicin dose.

Pharmacodynamics and Dosing Regimens

• Pharmacodynamics: Definitions and Definitions of Action

  • Definition: The study of drug effects and their mechanisms of action on the body.

  • Role: Guides drug selection, predicts efficacy and side effects, and informs therapeutic strategies.

  • Types of Action:

    • Agonist: Activates receptors (e.g., salbutamol).

    • Antagonist: Blocks receptors (e.g., propranolol).

    • Partial Agonist: Provokes partial receptor activation (e.g., buprenorphine).

• Mechanisms of Drug Action

  • Receptor Binding: Agonism or antagonism; e.g., lidocaine blocking sodium channels.

  • Enzyme Inhibition: Altering biochemical pathways; e.g., NSAIDs inhibiting cyclooxygenase ($COX$).

  • Ion Channel Modulation: Altering the flow of ions; e.g., amiodarone acting on potassium channels.

  • Direct Action: Physical or chemical effects; e.g., antacids neutralizing gastric acid.

• Dosing Strategies

  • Dosing Regimen: Includes the specific dose, frequency, route, and duration; e.g., amoxicillin $500\,mg$ every $8\,\text{hours}$.

  • Types of Doses:

    • Loading Dose: Used to reach therapeutic levels rapidly; e.g., digoxin $0.5-1\,mg$.

    • Maintenance Dose: Sustains the therapeutic effect; e.g., warfarin $2-5\,mg/day$.

    • Therapeutic Dose: The effective range of a drug.

    • Toxic Dose: A dose that causes harm to the patient.

  • Adjustments: Doses must be adjusted for age, weight, and organ function (e.g., pediatric-specific dosing).

Drug Interactions and Adverse Reactions

• Drug Interactions

  • Pharmaceutical Interaction: Physical or chemical incompatibility occurring before administration; e.g., ceftriaxone precipitating when mixed with calcium-containing IV fluids.

  • Pharmacokinetic Interactions ($PK$): One drug alters the ADME of another.

    • Absorption: Antacids reduce the absorption of tetracycline through chelation.

    • Metabolism: $CYP450$ inhibitors like erythromycin increase warfarin levels, increasing bleeding risk.

    • Excretion: Probenecid reduces the renal clearance of penicillin, prolonging its action.

  • Pharmacodynamic Interactions ($PD$): Altering effects at the target site.

    • Synergistic: Aspirin combined with warfarin increases bleeding risk.

    • Antagonistic: Beta-blockers counteracting the bronchodilation of salbutamol.

    • Additive: Alcohol combined with benzodiazepines enhances Central Nervous System ($CNS$) depression.

• Adverse Drug Reactions (ADR)

  • Classification:

    • Type A: Dose-dependent and predictable (e.g., NSAID-induced gastritis).

    • Type B: Idiosyncratic and unpredictable (e.g., penicillin anaphylaxis).

  • Toxic Effects: Specifically related to overdose; e.g., digoxin toxicity manifesting as arrhythmias and nausea.

  • Allergic Reactions: Immune-mediated responses such as rashes or anaphylaxis.

  • Drug Dependence: Physical or psychological reliance (e.g., opioids).

  • Tolerance: A reduced response to a drug over time (e.g., benzodiazepines).

  • Withdrawal Syndrome: Symptoms occurring upon cessation of a drug; e.g., opioid withdrawal causing nausea and agitation.

Clinical Practice and Research Stages

• Monitoring and Practitioner Control

  • Efficacy Monitoring: Observing clinical responses such as pain relief with analgesics or infection resolution with antibiotics.

  • Safety Monitoring: Utilizing laboratory tests (e.g., $INR$ for warfarin), screening for side effects, and therapeutic drug monitoring.

• Pharmacoeconomics and Pharmacoepidemiology

  • Pharmacoeconomics: Evaluates the cost-effectiveness of drugs (e.g., cost per $QALY$ for antibiotics) to optimize healthcare resource allocation.

  • Pharmacoepidemiology: The study of drug effects in large populations to assess safety, efficacy, and utilization patterns using cohort or case-control studies.

• Stages of Drug Research

  • Preclinical: Laboratory and animal studies to determine safety, efficacy, and toxicity ($LD_{50}$, carcinogenicity).

  • Clinical Phases:

    • Phase I: Safety and pharmacokinetics in healthy volunteers ($20-100$ subjects).

    • Phase II: Efficacy and dose-ranging in patient groups ($100-300$ subjects).

    • Phase III: Large-scale efficacy and safety trials ($1,000-3,000$ subjects).

    • Phase IV: Post-marketing surveillance to identify rare ADRs.

• Pharmacology in Special Populations

  • Pregnancy:

    • PK: Increased $V_d$ due to higher plasma volume and enhanced renal clearance.

    • PD: Altered sensitivity; avoid teratogens like tetracycline. Prefer safe options like amoxicillin.

  • Pediatrics (Newborns and Young Children):

    • PK: Immature liver/kidney function results in slower metabolism; higher $V_d$ due to increased body water.

    • PD: Increased sensitivity to drugs like opioids (respiratory depression). Weight-based dosing is critical, such as amoxicillin $20-40\,mg/kg/day$.

  • Elderly:

    • PK: Reduced renal/hepatic clearance; increased $V_d$ for lipophilic drugs like diazepam.

    • PD: Greater sensitivity to benzodiazepine sedation or opioid respiratory depression. Lower doses (e.g., warfarin) are often necessary.

Clinical Pharmacology of Specific Drug Classes

• Antimicrobial Therapy: General Principles and Penicillins

  • Principles: Selection based on pathogen and resistance, ensuring adequate duration and compliance.

  • Classification:

    • By Action: Bactericidal (e.g., penicillin) vs. Bacteriostatic (e.g., tetracycline).

    • By Structure: Beta-lactams, aminoglycosides, macrolides, fluoroquinolones.

  • Penicillins: Inhibit cell wall synthesis by binding to penicillin-binding proteins.

    • $\beta$-Lactamases: Bacterial enzymes that confer resistance.

    • Inhibitors: Clavulanic acid and sulbactam (e.g., amoxicillin-clavulanate).

    • Examples: Penicillin G (narrow-spectrum for streptococci) and amoxicillin (broader).

• Cephalosporins, Lincosamides, and Carbapenems

  • Cephalosporins: Inhibit cell wall synthesis. Broad-spectrum (e.g., ceftriaxone). Side effects include hypersensitivity and $C.\,difficile$ infection.

  • Lincosamides: Inhibit protein synthesis ($50S$ ribosome); e.g., clindamycin. Used for dental anaerobic infections. Side effects include a high risk of $C.\,difficile$ colitis.

  • Carbapenems: Inhibit cell wall synthesis. Very broad spectrum (e.g., meropenem). Used for multidrug-resistant infections. ADRs include seizures.

• Aminoglycosides, Macrolides, and Fluoroquinolones

  • Aminoglycosides: Inhibit protein synthesis ($30S$ ribosome); e.g., gentamicin. Spectrum: Gram-negative aerobes. Significant risks of nephrotoxicity and ototoxicity.

  • Macrolides: Inhibit protein synthesis ($50S$ ribosome); e.g., azithromycin ($t_{1/2} \approx 68\,\text{hours}$). Risk of $QT$ prolongation.

  • Fluoroquinolones: Inhibit DNA gyrase/topoisomerase; e.g., ciprofloxacin. Broad spectrum. Contraindicated in children and pregnancy due to tendonitis and $QT$ prolongation risks.

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  • Classification: Non-selective (inhibits $COX-1/COX-2$; e.g., ibuprofen) and $COX-2$ selective (e.g., celecoxib).

  • Mechanism: Inhibits cyclooxygenase to reduce prostaglandin synthesis, alleviating pain and inflammation.

  • Side Effects: Gastrointestinal bleeding, renal impairment, and cardiovascular risks.

  • Monitoring: Assessing pain relief, renal function (creatinine), and blood pressure.

• Glucocorticoids

  • Classification: Short-acting (hydrocortisone), intermediate (prednisolone), and long-acting (dexamethasone).

  • Mechanism: Bind glucocorticoid receptors and inhibit inflammatory cytokines.

  • Adverse Effects: Osteoporosis, hyperglycemia, weight gain, adrenal suppression, and increased infection risk.

  • Monitoring: Blood glucose, bone density, and resolution of symptoms like oral inflammation.